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Abstract.  Insertion of a crude preparation of cyclic 
AMP (cAMP)-dependent protein kinase inhibitor 
(PKI) into a cloned mouse anterior pituitary cell line 
(AtT-20/D 16-16) blocked cAMP-mediated hormone 
release.  This was accomplished by developing a tech- 
nique to incorporate PKI into multicellular cultures. 
The technique involved the encapsulation of the PKI 
into liposomes coupled to Protein A (a bacterial pro- 
tein that binds to the Fc portion of antibodies). Appli- 
cation of such liposomes to AtT-20 cells targeted by 
pre-treatment with an antiserum against neural cell 
adhesion molecule (a cell surface glycoprotein ex- 
pressed by these cells) resulted in the attachment of 
the liposomes onto the cell surface followed by the 
delivery of the liposome content into the cells. The 
AtT-20 cells respond to cAMP-promoting agents such 
as forskolin by secreting the hormone adrenocortico- 
tropin (ACTH). Liposomes containing PKI and cou- 
pled to protein A specifically blocked cAMP-mediated 
ACTH release from cells treated with anti-N-CAM 
antibodies. In contrast, the ACTH release response to 
K + or phorbol esters does not appear to involve 
cAMP and was not reduced by such manipulations. 
The specificity of PKI to block hormone release initi- 
ated by one but not by other secretagogues directly 
links cAMP-dependent protein kinase with the ACTH 
release process but suggests that there are other mech- 
anisms also involved in stimulus-secretion coupling in 
corticotrophs. 
S 
ECOND messengers are believed to mediate the physio- 
logic effects of hormones and neurotransmitters.  One 
such second messenger is cyclic AMP (cAMP).  t This 
cyclic nucleotide  is  found in  most  mammalian cells and 
increases in its intracellular levels accompany activation of 
cell surface hormone receptors (22, 32). cAMP stimulates 
protein kinases that in turn catalyze the phosphorylation of 
different cytoplasmic and  membrane-bound  proteins  (22). 
These phosphoproteins are considered to be crucial in me- 
diating the physiologic actions of cAMP. 
Demonstration of  the biologic role of  these phosphorylation 
events has proven difficult to accomplish since simultaneous 
measurement of cAMP-dependent protein kinase activity or 
cAMP-mediated protein  phosphorylation  and the biologic 
response ascribed to  cAMP  is  not  easy to  perform.  One 
approach has used pressure injection of the catalytic subunit 
of  cAMP-dependent protein kinase or protein kinase inhibitor 
(PKI) to evoke or block cAMP-dependent responses (6,  10, 
1. Abbreviations used in this paper: cAMP, cycfic AMP; CF, carboxyfluoresoein; 
DME, Dulbeceo's modified Eagle's medium; MTX, methotrexate; N-CAM, 
neural cell adhesion molecule; PKI, protein kinase inhibitor. 
22). For example, injection of the catalytic subunit of cAMP- 
dependent protein kinase into individual Aplysia neurons was 
shown to both facilitate the phosphorylation of  several distinct 
proteins and alter  K  + conductance  (6,  10,  12,  22,  38). In 
contrast,  injection  of the  PKI  protein  into  these Aplysia 
neurons reduced the ability of cAMP and agonists that stim- 
ulate adenylate cyclase activity to affect the electric activity 
of these cells (1). 
This experimental approach is limited to studies on single 
cells. Physiologic responses such as hormone  secretion can 
not  be  easily examined  from  single cells, thus effectively 
excluding similar determination  of the intracellular mecha- 
nisms involved in stimulus-secretion coupling. It would there- 
fore be advantageous to develop techniques to incorporate 
into multiceUular systems substances normally impermeable 
to cell membranes such as PKI to bypass the use of injecting 
electrodes. This would aid in the determination of  the relative 
importance of various second messengers in the physiology 
of the cell. 
Liposomes have been used to target pharmacologic agents 
such as methotrexate (MTX) or folic acid to cells in vitro (l 3, 
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molecule  into  phospholipid  vesicles which  are  specifically 
directed to target cells via monoclonal antibodies covalently 
coupled to their outer membrane. Alternatively, the liposomes 
can be coupled to Staphylococcus aureus protein A which will 
confer onto the  liposomes the ability to  bind to cells pre- 
treated with antibodies with specificity for a particular antigen 
expressed at the cell surface. In the present study, we report 
the adaptation of this method to study the intracellular proc- 
esses of stimulus-secretion coupling. In particular, it is shown 
that a crude preparation of PKI can be entrapped into lipo- 
somes and  targeted  to  a  tumor cell  line  (AtT-20/D16-16) 
derived from the mouse anterior pituitary using anti-neural 
cell adhesion molecule (N-CAM) antibodies. These cells se- 
crete adrenocorticotropin (ACTH) (4,  9,  20,  26,  29-31,  35) 
and both cAMP and cAMP-dependent protein kinase have 
been implicated in the receptor-mediated release of this hor- 
mone (3, 8,  I l,  16, 21, 42). Once inside the AtT-20 cells, the 
PKI blocks the ACTH release response to cAMP and cAMP- 
promoting agents but not to secretagogues that do not activate 
cAMP-dependent protein kinase activity. 
Materials and Methods 
Forskolin was purchased  from Calbiochem-Behring Corp. (Los Angeles, CA). 
8-Bromo-cAMP,  isobutylmethylxanthine,  KCI, human serum albumin,  and 
PKI (crude,  from rabbit  muscle) were from Sigma Chemical Co. (St. Louis, 
MO).  Phorbol  12,13-dibutyrate was a gift of Dr.  S. Jaken,  National  Cancer 
Institute,  Bethesda, MD. Dulbecco's modified Eagle's medium (DME) (4,500 
rag/liter  of glucose) was obtained  from GIBCO (Grand Island, NY). Fetal calf 
serum was from North American Biologicals (Miami, FL) and human ACTH 
(synthetic)  and  anti-serum  were  gifts from the  National  Pituitary  Agency 
(Baltimore, MD). ~251-1abeled human ACTH was from Immuno Nuclear Corp 
(Stillwater, MN) and goat anti-rabbit  immunoglobulin was from Cappel Lab- 
oratories (Cochranville, PA). The cAMP immunoassay  kits were from Becton- 
Dickinson and Co. (Rutherford,  NJ). 
Cell Culture Technique 
Mouse AtT-20/Dl6-16 tumor cells (originally subcloned by S. Sabol, National 
Institutes of Health) were grown and subcultured  in DME with  10% fetal calf 
serum as previously  described  (9). Cells were plated  in 96-well flat-bottom 
tissue culture clusters at an initial density of 5 x  l04 cells per well. The cells 
were grown for 48-96 h to near confluency in 100 pl of culture medium. 
A nti-N-CAM Antibodies 
Polyclonal anti-N-CAM antibodies  were obtained  from a rabbit  immunized 
with an antigen preparation  purified as previously described on a monoclonal 
H28 anti-N-CAM immunoaffinity  column from adult  mouse brain (33). The 
antibodies obtained  through such a procedure revealed on Western blots only 
the bands detected by the monoclonal H28. Results previously reported (7, 36) 
showed the specificity of this antiserum  for N-CAM molecules and the ability 
of its Fab' fragments to specifically inhibit the aggregation of a neuroblastoma 
cell line (NE  l.115). 
Immunofluorescence Studies 
Cells were seeded on polylysine-coated glass coverslips and grown for 2-4 d 
and then immunolabeling  experiments using anti-N-CAM antibodies together 
with species-specific fluorescent  labeled anti-lg  antibodies  were done as de- 
scribed (34). When  the liposomes were tested, they were incubated  with the 
cells in  place  of the  second  antibody.  The liposomes  were  diluted  10:100 
(240:24 pM carboxyfluorescein [CF] in the liposomes, respectively) in culture 
medium and applied to the cells for at least 3 h at room temperature,  and then 
the coverslips were washed three times with DME and mounted in phosphate- 
buffered saline (pH 7.4). The slides were immediately  viewed under a Zeiss 
photomicroscope equipped with a fluorescent attachment.  The slides were then 
photographed  on Kodak  Ektachrome  200 film. Due to the incompatibility  of 
liposomes with any kind of postfixation  process, some cells tended to retract 
from one another and adopt a round shape while under examination  (Fig. I C). 
MTX-containing  Liposomes 
To test the endocytic potential of the N-CAM antigen at the surface of AtT-20 
cells, we prepared small unilamellar  vesicles containing  CF (Eastman  Kodak 
Co.,  Rochester  NY; purified  by crystallization  and filtration  over Sephadex 
LH20 according to Ralston et al. [27]) and MTX (Sigma Chemical Co.). Briefly, 
an  organic  solution  containing  17  #tool  dipalmitoyl  phosphatidyl  choline 
(Avanti  Polar  Lipid& Inc.,  Birmingham,  AL),  10  pmol  cholesterol  (Sigma 
Chemical Co.; recrystallized in ethanol), and l pmol of N-[3-(2-pyridyl)dithio]- 
propionyl dipalmitoyl phosphatidyl ethanolamine  (synthesized as described by 
Barbet et  al.  [5]) was evaporated  to dryness  under argon,  then 3 ml of an 
aqueous  solution  of CF (50 mM) and MTX (25 mM) was added,  heated to 
50"C and vortexed for ~5 min. The resulting turbid suspension of  multilamellar 
liposomes was then sonicated for 30 rain at 50"C using a W-375 probe sonicator 
(Heat Systems-Ultrasonics, Inc., Farmingdale, NY). The clear liposome prep- 
aration  was centrifuged (2,000 g,  10  min) to remove titanium particles, and 
chromatographed  on Sephadex G50 (0.9  x  30  cm) in phosphate  buffer  to 
separate liposomes from solutes not entrapped. 
Small unilameUar vesicles containing CF and MTX were then coupled to S. 
aureus Protein A (Pharmacia Fine Chemicals) as described by Leserman et al. 
(14). Protein A (1 mg; 8.7 x  10  ~ cpm of ~251-radiolabeled Protein A in 300 pl 
of phosphate buffer) was reacted with a 10-fold molar excess of N-succinimidyl 
3-(2-pyridyl)dithiopropionate (Pharmacia Fine Chemicals, Piscataway, N  J) for 
1 h at room temperature. Then, dithiothreitol (Sigma Chemical Co.) was added 
to  the  reaction  mixture  at  a  50  mM  final  concentration.  After  a  20-min 
incubation at room temperature,  the mixture was chromatographed  on a PDI0 
column in phosphate-buffered saline (pH 8.0). The thiol-derivatized Protein A 
(600 pg in 0.5 ml) was added to the liposome preparation  (9 umol total lipids 
in  1.5  ml)  and  incubated  for  24  h  at  room temperature.  Liposomes were 
separated  from uncoupled  Protein  A  by chromatography  on  Sepharose 4B 
(Pharmacia  Fine Chemicals; column,  1.6 x  30 cm). Liposomes eluted in the 
void volume (as demonstrated  by the presence of encapsulated CF) together 
with 21% of the total Protein A (evaluated from recovered ~251). 
PKl-containing Liposomes 
The PKI was dissolved in distilled water to a final concentration  of 10 mg/ml 
and used without further purification. Radioiodination  was performed accord- 
ing to Salacinski et at. (37). To a small plastic vial containing  9 ~g iodogen 
were added 20 pl of 0.05 M phosphate buffer (pH 7.0), 200 #g PKI diluted in 
150  pl  phosphate  buffer,  and  1 mCi  ~251-sodium iodide.  After  10  min of 
incubation  at room temperature,  the reaction mixture was diluted with 400 pl 
of 0.05 M phosphate buffer and applied onto a Sephadex G-25 column (PD10 
column;  Pharmacia  Fine Chemicals). The labeled fractions (1  ml,  100 pCi) 
were pooled and stored at 4"C until used. 
Since molar concentrations  of PKI as large as those used for CF and MTX 
cannot be  practically  attained,  liposomes  with  larger internal  volumes  and 
entrapment efficiencies were prepared for the PKI studies. Thus, reverse-phase 
evaporation vesicles were made according to Szoka and Papahadjopoulos (40). 
Dimyristoyl phosphatidyl choline (21.6 pmol, Avanti Polar Lipids, Inc.), dipal- 
mitoyl phosphatidyl serine (4 umol, Avanti Polar Lipids, Inc.), cholesterol (14 
tzmol), and N-[3-(2-pyridyl)dithiopropionyl dipalmitoyl  phosphatidyl ethanol- 
amine (0.4 #mol) were dissolved in 2 ml diethyl ether. An emulsion  between 
the lipid ethereal solution and an aqueous phase (1  ml) containing  PKI (6.5 
mg, 2 x  10  7 clam transferred into phosphate-buffered saline by PDI0 filtration) 
and  CF  (40  mM)  was  made  without  sonication  using  two  glass syringes 
connected  by a three-way stopcock (18). The emulsion  was then evaporated 
under reduced pressure (0.5-0.8 atm) at room temperature  in a rotary evapo- 
rator.  The  liposome  suspension  was extruded  sequentially through  0.4- and 
0.2-urn polycarbonate  filters (Nucleopore,  Pleasanton, CA) as described (24). 
PKI and CF not entrapped  were removed by gel filtration on a Sepbarose 4B 
column (1.6 x  30 cm). The liposome peak contained  6% of the total inhibitor 
(9 x  l0  s cpm) and 6.4% of the total CF. 
Protein A was coupled to PKI-containing liposomes as described above; N- 
succinimidyl  3-(2-pyridylRfithiopropionate-modified  Protein  A, activated  by 
reduction  with dithiothreitol  (465 pg,  1.5  x  l06 cpm, in  1.5  ml phosphate- 
buffered saline) was reacted with 3 ml of the liposome preparation  (18 umol 
lipids,  180 pg PKI,  5 x  l0  s cpm) for 24 h at room temperature.  Liposomes 
were then separated from uncoupled  Protein A by gel filtration on Sepharose 
4B ( 1.6 x 30 cm). The percentage of coupled Protein A is ~5%. In experiments 
with no entrapped PKI (control liposomes with no PKI but coupled to Protein 
A),  this  percentage  was  more  precisely  measured  to  be  ~10%.  The  final 
preparation contained  35 tzg/ml PKI and 0.23 mM CF and ~9 pg/ml Protein 
A with ~3 mM total lipids. 
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Before the experiments, cells were washed with DME and incubated for 1 h at 
25"C with anti-N-CAM antibodies ( 1:300 dilution). The cells were then washed 
again with DME and the liposomes or the free MTX in 100 ul of medium were 
applied for 3 h at 37"C. After the incubation,  50 t*l of DME containing  [3H]- 
deoxyuridine (0.5 uCi; New England Nuclear, Boston, MA, 18 Ci/mmol) were 
added for 10 h at 37"C. Then the cells were washed and harvested on fiber glass 
filters and tritium  was measured by liquid scintillation spectroscopy. 
Procedures for ACTH Release 
Before the experiments,  the AtT-20 cells were washed twice with  100 ul of 
DME containing  25 mM Hepes and 2% fetal calf serum. The ceils were then 
incubated  with 50 ~1 of medium with or without the anti-N-CAM  antibody 
(final dilution of 1:300) for 1 h at 25"C. The cells were then washed twice and 
incubated  for 3 h (unless otherwise indicated) at 37"C with  100 t~l of medium 
containing  either  PKI,  liposomes  (with  or without PKI)  either  lacking  or 
coupled to Protein A. At the end of this time, the medium was removed and 
fresh DME containing  forskolin, K ÷, or phorbol 12,13-dibutyrate was applied 
to the cells and incubated for 30 rain at 37"12. An aliquot of the medium was 
removed and frozen at -20"C for later analysis of ACTH immunoreactivity. 
Experiments  involving 8-bromo-cAMP  were for 60 min in order to observe 
significant stimulation  of ACTH release. Forskolin and phorbol 12,  13 dibu- 
tyrate were dissolved in ethanol and stored as 10-raM stock solutions. The final 
concentration  of ethanol  (0.5% in the forskolin  experiments)  did  not affect 
ACTH release by itself. Experiments were done in triplicate wells and in most 
cases repeated 3--4 times on different subcultures. The cell density did not vary 
appreciably between wells on the same plate. For this reason most experiments 
were performed on a single 96-well plate at a time and ACTH release values 
were not corrected for differences in cell number. 
ACTH Immunoreactivity 
ACTH immunoreactivity  was measured as previously described (9). The anti- 
body used was specific for the 14-24 segment of ACTH. 
cAMP Determination 
Similar procedures as described for ACTH release were used. However, follow- 
ing the liposome pre-treatment,  100 ~1 of DME (25 mM Hepes) containing 0.5 
mM isobutyl methylxanthine  with or without forskolin was applied for 30 rain. 
The medium was then removed,  100 ul of 0.5 N HCI was applied, and the 
tissue sonicated in the well. The samples were then analyzed for cAMP using 
the  Becton-Dickinson  radioimmunoassay  kit  as  previously  described  (28). 
Values  are  expressed  as  pmol/well  and  are  the  means _  SEMs  of three 
determinations. 
Results 
Targeting of  Protein A-bearing Liposomes to ART-20 
Cells Using Anti-N-CAM Antibodies 
The expression of  the neural cell adhesion molecule (N-CAM) 
at the cell surface of  AtT-20 cells was demonstrated by indirect 
immunofluorescence (Fig.  1, A  and B) and immunoprecipi- 
tation (not shown). When live AtT-20 cells were labeled with 
anti-N-CAM antibodies and fluoresceinated goat anti-rabbit 
antiserum,  all  the  cells  in  the  culture  fluoresced  brightly. 
Binding of the protein A-bearing liposomes to AtT-20 cells 
pre-treated with anti-N-CAM antibodies was easily visualized 
by fluorescence microscopy since the liposomes contained CF 
(Fig.  1,  C  and  D).  The  fluorescent  liposomes  appeared  as 
small bright grains at the surface of the cells (Fig.  1, C2 and 
D2). Although the incubations were done at room tempera- 
ture,  perinuclear  fluorescence  in  some  cells  indicated  the 
endocytosis of some vesicles (Fig.  1, D1). By contrast, cells 
treated with anti-N-CAM antibodies and then reacted with 
liposomes not coupled to Protein A did not show cell-associ- 
ated fluorescence (Fig.  1, E  and F) indicating that Protein A 
mediates the liposome attachment to the antibody. The same 
absence of binding of the liposome-protein A conjugates was 
also observed when the cells were preincubated with a preim- 
mune antibody (Fig. 1, G and H), indicating that Protein A- 
coupled liposomes by themselves cannot bind to the cells and 
resulting in the necessity of the specific interaction of N-CAM 
molecules with their antibodies before liposome attachment. 
Delivery of the Content of  Liposomes Targeted to 
AtT-20 Cells with Anti-N-CAM Antibodies 
To test the capacity of  the target N-CAM molecule to mediate 
internalization and delivery of  the liposome content into Aft- 
20 cells,  we prepared liposomes containing MTX coupled to 
Protein  A.  MTX  has  the  ability  to  inhibit  the  intra-cyto- 
plasmic enzyme,  dihydrofolate reductase,  and  this  effect is 
readily monitored by measuring the inhibition of [3H]deoxy- 
uridine incorporation into DNA of replicating cells. AtT-20 
cells treated with anti-N-CAM antibody and exposed (for 3 
h)  to  MTX-containing  liposomes  coupled  to  Protein  A 
showed reduced [3H]deoxyuridine incorporation (Fig. 2). The 
inhibition of [3H]deoxyuridine incorporation was dependent 
on the concentration of  MTX-containing liposomes. A similar 
inhibition curve was observed with free MTX (Fig. 2). How- 
ever,  such  liposomes containing MTX  applied  to cells  not 
pre-treated with anti-N-CAM antibodies or pre-treated with 
an irrelevant antibody did not affect [3H]deoxyuridine incor- 
poration (Fig. 2). These results further confirm the specificity 
of the technique and demonstrate the endocytic potential of 
N-CAM as a target antigen. 
Incorporation of cAMP-dependent PKI into 
AtT-20 Cells 
Experiments were conducted to determine whether free PKI 
could be incorporated into  AtT-20 cells  and block cAMP- 
mediated ACTH release.  When applied to AtT-20 cells,  the 
PKI did not block the ACTH release response (Table  I) to 
forskolin, an agent that activates adenylate cyclase and cAMP- 
Figure 1. Immunofluorescent detection of N-CAM antigen expression and liposome binding. Cells were grown on polylysine coverslips. The 
live cells were washed and reacted with polyclonal anti-N-CAM antibodies at 1:1,000 dilution or preimmune serum at 1:300 dilution in culture 
medium for 30 min at room temperature.  The coverslips were then washed in DME and reacted either with a goat anti-rabbit  fluorescein- 
linked antibody at 1:100 dilution for 30 min (A and B), then washed again and fixed in acid/alcohol  for 10 rain at 10*C  before being mounted 
in PBS and glycerol, or with different preparations  of liposomes at 24 uM CF culture medium (C-H) for 3 h at room temperature.  A, C, E, 
and G are phase-contrast images whereas B, D, F, and H are fluorescent photographs of the same fields. For liposomes, the fixation step was 
omitted and the cells were immediately examined under the microscope. For C and D, the cells were reacted with anti-N-CAM antibodies and 
liposomes linked with Protein A and containing CF and PKI. Two different experiments are shown with focus either on the cell surface (C2 
and D2) or intracellularly (CI and D 1). The liposomes bound to the surface of the cell appeared like small individual fluorescent dots. For E 
and F the cells were reacted with the same preparation  of liposomes lacking Protein A; for G and H the anti-N-CAM antibody was replaced 
by preimmune serum. Bars, 10 tLm. 
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(8,  16,  21).  Pre-treatment of the AtT-20 cells with anti-N- 
CAM antibodies was not sufficient to allow the PKI to block 
stimulated ACTH secretion nor was co-treatment of the ceils 
with free PKI and liposomes coupled to Protein A  but not 
containing PKI (Table I). These results indicate that free PKI 
cannot gain access to ART-20 cells. 
When PKI was encapsulated into the liposomes coupled to 
Protein A  and applied to AtT-20 ceils pre-treated with anti- 
N-CAM antibodies, forskolin-stimulated ACTH release was 
abolished (Table I). The blockade of  forskotin-induced ACTH 
secretion required both pre-treatment of  the AtT-20 cells with 
anti-N-CAM antibodies and liposomes coupled to Protein A 
(Fig.  3).  Neither the anti-N-CAM antibodies nor the lipo- 
somes coupled to protein A but not containing PKI reduced 
forskolin's effect on  ACTH  release (Fig. 3).  Application of 
protein A-bearing liposomes containing PKI to AtT-20 cells 
pre-treated with anti-N-CAM antibodies also diminished 8- 
bromo-cAMP (0.1  mM)-stimulated ACTH release (control, 
basal =  0.12 +  0.01; 8-bromo-cAMP =  0.44 +_ 0.05; signifi- 
1  O0 
a: 
D  >- 
u~ 
£3 
~  5o 
3 
z 
0 
cantly different from basal, P  <  0.05  using a Student's t test; 
treated, basal =  0.14 _+ 0.03; 8-bromo-cAMP =  0.21  _+ 0.04, 
values in  ng  ACTH/well  are  the  means  _  SEMs  of three 
experiments done in triplicate wells). 
The incorporation of the PKI into AtT-20 cells appeared 
to  specifically block cAMP-mediated ACTH  release. Thus, 
neither K+ nor phorbol esters stimulate ACTH secretion by 
activating cAMP-dependent protein kinase and treatment of 
anti-N-CAM antibody labeled AtT-20 cells with Protein A- 
bearing liposomes containing PKI did not affect the ACTH 
release  response  to  either  of these  secretagogues (Fig.  4). 
Furthermore, the inhibition of forskolin-stimulated  ACTH by 
the liposome-PKI treatment was not due to a  blockade of 
adenylate cyclase activity since  forskolin-stimulated cAMP 
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Figure 2.  Delivery  of MTX  to  cells  by  targeting  of the  N-CAM 
molecules. Cells were seeded at a  density of 5  x  104 cells per well in 
96-well tissue culture clusters and cultured for 48 h. For the experi- 
ments, they were incubated with anti-N-CAM antibodies at a  1:300 
dilution  for  1  h  at room temperature (0 and A) or with  medium 
alone (0), then washed and reacted either with free MTX (O), or with 
Protein A linked to MTX containing liposomes (MTX LIPO) (0 and 
A) at different concentrations for 3 h at 37°C in 100 ul of medium. 
Then 50 ul of medium containing 0.5 ,Ci of [aH]deoxyuridine  were 
added, and the incubation was continued for  l0 h.  Then the cells 
were harvested and the radioactivity  counted. Each point is the mean 
of triplicate wells. The bars represent the SEM. The  100% control 
values are the mean of [3H]deoxyuridine  incorporation by the cells 
incubated without MTX  or liposomes which  was 23,800  ±  1,190 
cpm (n =  12). The values on the abscissa are given as the logarithm 
of nM concentrations. 
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Figure 3. Protein  A-bearing liposomes containing  PKI targeted to 
AtT-20 cells labeled with N-CAM antibody block forskolin-sfimu- 
lated ACTH release. Cells were exposed for 1 h at room temperature 
to 50/A of DME containing 2% fetal calf serum with or without the 
anti-N-CAM antibodies (AB) at a final dilution of 1:300. The cells 
were washed and then treated for 3 h at 37°C in an atmosphere of 
10% COz with liposomes containing the PKI (0.18 #g PKI) (LIPO), 
liposomes containing the PKI but not coupled to Protein A (LIPO- 
PA), liposomes coupled to Protein A but lacking the PKI (LIPO- 
PKI), or DME alone. Cells exposed only to medium were represented 
as CONTROL. After  this incubation, the cells were washed and basal- 
(open bars) or forskolin- (50  /zM) stimulated (dosed bars) ACTH 
release was measured. Results represent the mean ±  SEM of four 
separate experiments done in triplicate wells. The ACTH release in 
response to forskolin is significantly different (using a Student's t test) 
than basal ACTH release from the same treatment except in the case 
of cells treated with AB + LIPO. 
Table L Effect of PKI on Forskolin-stimulated ACTH Release 
ACTH release (ng/well) 
AB+  AB+  AB+ 
Condition  Control  AB  (LIPO+PKI)  PKI  PKI  PKI+ (LIIK)-PKI) 
Basal  (12)0.27  ±0.03  (12)0.30+_0.03  (12)0.25 _+.0.02  (3)0.27  ±0.03  (3)0.23 ±0.03  (3)0.21  ±0.01 
Forskolin  (12) 0.60 ±  0.06*  (12) 0.61 _+ 0.06*  (12) 0.30 ±  0.02  (3) 0.55 ±  0.04*  (3) 0.57 ±  0.04*  (3) 0.49 ±  0.03* 
AtT-20 oflls were treated for 1 h with DME with or without anti-N-CAM antibodies (AB)  at a  1:300 dilution. The cells were then washed and treated with either 
PKI (0.5 t~g/100 ~), liposomes containing PKI (0.18 I~,/100,1) coupled to protein A (LIPO+PKI),  or liposomes coupled to Protein A but not containing PKI 
(LIPO-PKI). At the end of this time the cells were washed and either basal- or forskolin-  (50/~M) stimulated ACTH release was measured. Results are the mean 
+ SEM of(N) experiments done in triplicate wells. 
* P < 0,05 (using a Student's t test) different from basa/ACTH release from the same treatment. 
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Figure 4. Liposomes containing PKI specifically inhibit the ACTH 
release response to forskolin. Cells were exposed for  1 h at RT to 
DME with 2% fetal calf serum with or without anti-N-CAM anti- 
bodies (AB). The cells were then washed and treated for 3 h at 37"C 
with medium either with or without liposomes containing  PKI (0.18 
#g PKI) coupled to Protein A. The cells were washed and stimulated 
for 30 min with either forskolin (50 vM), phorbol  12,13Mibutyrate 
(1 uM), or K+ (50 raM). The results are the means ± SEMs of four 
experiments done in triplicate wells. The ACTH release in response 
to forskolin is significantly different (P < 0.05 using a Student's  t test) 
from basal ACTH release in the control and AB treatments.  The 
ACTH release in response to K + and phorbol  12,13-dibutyrate is 
significantly different (P < 0.05, using a Student's t test) from basal 
release in the Control, AB, and AB + LIPO treatments. 
Table IL Effect of  Protein A-bearing Liposomes Containing 
PKI on Forskolin-stimulated cAMP Formation 
cAMP 
(pmol/well) 
Condition  Control  AB  AB+LIPO 
Basal  2.2 + 0.5  2.6 __- 0.4  1.2 + 0.3 
Forskolin  108.0 _  15.1"  77.0 ± 2.8*  83.0 + 3.5* 
AtT-20 cells  were exposed to medium  with or without anti-N-CAM  antibody 
(1:300 dilution)  (AB) for 1 h. The cells  were washed and then exposed for 3 h 
to medium with or without liposomes containing  PKI (0.18 ~g/100 ~1) and 
coupled to protein A (LIPO). The cells  were then washed and either basal-  or 
forskulin-  (50 uM) stimulated  cAMP  accumulation  was measured. Results  are 
the mean + SEM or three experiments  done in triplicate  wells. 
* P < 0.05 (using  a Student's  t test) different  than basal cAMP levels  from the 
same treatment. 
accumulation was not reduced by this manipulation (Table 
II). 
The blockade of forskolin-stimulated ACTH release from 
AtT-20 cells was dependent on the concentration  ofliposomes 
(containing PKI) applied to  the cells and the time of pre- 
treatment (Fig. 5).  The actions of the PKI, once inside the 
AtT-20 cells, were relatively long lasting since forskolin could 
not stimulate ACTH release from cells 2 h after termination 
of the liposome treatment (Fig. 6). 
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Figure 5. Time and dose dependency for the inhibition  of forskolin- 
stimulated ACTH release by liposomes containing PKI. Cells were 
treated for i h with DME and anti-N-CAM antibodies (1:300 dilu- 
tion). (A) Cells were then washed and exposed for 3 h at 37"C to 
different  concentrations  of liposomes coupled  to  Protein  A  and 
containing PKI.  The cells were washed and medium with (©) or 
without (@) forskolin (50 #M) was applied for 30 min. ACTH release 
is the mean _+ SEM of three experiments done in triplicate wells. On 
the  abscissa are  represented  the  amounts of PKI present  in the 
different liposome concentrations exposed to the ceils. (B) Cells were 
washed and exposed to liposomes coupled to Protein A and contain- 
ing PKI (0.18 ~g in  100 #1 of liposome preparation)  for different 
periods of time. After washing, the cells were incubated for 30 min 
with DME with ((3) or without (O) forskolin (50 #M). ACTH release 
is the mean _+ SEM of three experiments done in triplicate wells. (A) 
ACTH release in response to forskolin was significantly different (P 
<  0.05, using a Student's t test) than basal ACTH release after the 
treatment with 0.02, 0.04, and 0.08 ug PKI/100 #1. (B) ACTH release 
in response to forskolin was significantly different (P < 0.05, using a 
Student's  t test) than basal ACTH release after 0.5  and  1 h  pre- 
treatment with the PK/. 
Discussion 
The results of this study further support the role of cAMP in 
the release of ACTH. Previously, it was shown that cAMP- 
dependent protein kinase was present in corticotrophs and 
could be activated by the hormones corticotropin-releasing 
factor and eatecholamines as well as by the direct activator of 
adenylate cyclase,  forskolin (3,  16,  21).  However,  the  link 
between the  activation of cAMP-dependent protein kinase 
and the ACTH secretory event had not been established. The 
ability of cAMP-dependent protein  kinase to  catalyze  the 
phosphorylation of exogenously applied histone proteins and 
endogenous substrates is blocked by the PKI (21). Encapsu- 
lating PKI into liposomes coupled to protein A and applying 
these liposomes to AtT-20 cells pre-treated with anti-N-CAM 
antibodies solved the problem of the inaccessibility  of PKI to 
intact cells. The ability of this treatment to prevent forskolin 
and 8-bromo-cAMP from releasing ACTH indicates that the 
activation of cAMP-dependent protein kinase is required for 
stimulus-secretion coupling evoked by forskolin in these tu- 
mor cells.  Demonstration of the  precise manner by which 
cAMP is involved in ACTH release will have to await the 
identification and functional characterization of the endoge- 
nous substrates for cAMP-dependent protein kinase in corti- 
cotrophs. 
The inability  of PKI to affect the hormone release response 
to the membrane depolarizing agent K + or the protein kinase 
C  activator,  phorbol  ester,  indicates that  the  intracellular 
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Figure 6. Persistent inhibition of forskolin-stimulated ACTH release 
by treatment of ART-20 cells with liposomes containing PKI. AtT-20 
cells were treated for  1 h  at  room temperature with anti-N-CAM 
antibodies (1:300).  The  cells were washed and exposed for 3  h  to 
DME with (0) or without (O) liposomes containing PKI (0.18  gg/ 
100 ~1) coupled to Protein A. At the end of this time the cells were 
exposed to forskolin (50 uM) for varying periods and ACTH release 
measured. ACTH release at 0  time of forskolin stimulation was the 
same as basal release (control =  0.60 +  0.1  ng/well; treated =  0.50 _+ 
0.09 ng/well). Basal release in control and liposome-treated cells did 
not vary appreciably during the stimulation periods (control, 0.5 h = 
0.61  +  0.1;  1 h  =  0.63  -+ 0.04;  2  h  =  0.64 +_ 0.08; treated, 0.5  h  = 
0.47  +  0.08,  1 h  =  0.65  +  0.1; 2  h  =  0.68  +  0.1, all values in ng/ 
well).  The  results are the mean  +  SEM  of ACTH  release in three 
experiments done in triplicate wells. ACTH  release in response to 
forskolin was different (P <  0.05, using a Student's t test) than basal 
release in control cells at 0.5,  1, and 2 h of stimulation time. 
events initiated by these secretagogues to cause ACTH secre- 
tion are distinct from those associated with cAMP. Previously, 
K ÷ was shown not to increase cAMP accumulation (28)  or 
cAMP-dependent protein kinase activity (16) in AtT-20 cells. 
Its mode of stimulating ACTH release may involve changes 
in calcium influx or mobilization as proposed by Richardson 
(29)  and inferred from electrophysiological data of Adler et 
at. (2) and Surprenant (39). 
Phorbol ester is believed to activate protein kinase C (23), 
an enzyme present in AtT-20 cells (25). The inability of PKI 
to inhibit phorbol ester-stimulated ACTH release suggests a 
distinction between the mechanism by which cAMP-depend- 
ent protein kinase and protein kinase C evoke ACTH secre- 
tion. Elucidation of the phosphorylation events initiated by 
the two kinases should aid in further determining the precise 
manner by which these two enzymes regulate hormone secre- 
tion. The ability to introduce substances into endocrine cells 
that  can  specifically mimic or antagonize  the  secretion  of 
hormone induced by cAMP, K +, or phorbol ester should aid 
in  elucidating  the  means  by  which  the  individual  second 
messengers modify hormone secretion. This, in turn, should 
help to determine the role of these intracellular pathways in 
transducing the physiological stimuli that regulate secretion. 
The  procedures used  in  the  liposome technique  did  not 
produce artifactual effects on ACTH release from the AtT-20 
cells. The anti-N-CAM antibodies did not reduce stimulated 
hormone secretion and liposomes lacking PKI did not alter 
ACTH release from control or anti-N-CAM antibody-treated 
cells.  Furthermore, in order for liposomes to attach to and 
deliver their contents into AtT-20 cells, it was necessary that 
they be coupled to protein A and that the AtT-20 cells be pre- 
treated with  anti-N-CAM  antibodies.  This conclusion was 
initially formulated from the results of the studies with CF 
and MTX (see also references 5,  13,  15, and 36). 
Between 1 and 2 h of liposome treatment was required to 
incorporate enough PKI into the ART-20 cells to completely 
abolish forskolin-stimulated ACTH release. This time course 
is similar to that observed for the delivery of MTX or CF 
encapsulated in liposomes targeted to other cell types with 
specific cell  surface antibodies  (41).  The time lag  may be 
related to the process of endocytosis or to the transport of 
PKI  molecules  to  the  cellular  compartments  containing 
cAMP-dependent protein kinase. 
Once  incorporated  into  AtT-20  cells,  the  PKI  blocked 
forskolin  evoked ACTH  release  for several hours.  Similar 
results were obtained in Rl 5 cells of the Aplysia in which PKI 
was pressure injected into these neurons and the ability of 
cAMP to increase K ÷ conductance  measured (1,  22).  This 
suggests that PKI is relatively stable in the cell and not rapidly 
inactivated or excluded. 
The  delivery  of encapsulated  materials to  targeted  cells 
seems to be best achieved using small or intermediate-sized 
liposomes (25-200 nm) (17). The formation of  such liposomes 
involves the  exposure  of the  solutes  to  either  sonication, 
detergents,  or  organic  solvent.  The  mechanisms by which 
entrapped solutes gain access to the cell cytoplasm are not 
well understood.  Receptor-mediated endocytosis and subse- 
quent transfer of the liposomes to acidic intracellular vesicles 
which eventually fuse with lysosomes have been proposed for 
the targeted delivery of encapsulated MTX or CF (19). This 
would  imply further exposure of the  solutes to  potentially 
denaturing environment as well as hydrolytic enzymes. The 
liposome technique might therefore not be adaptable to all 
molecules. 
With  the  development of antibodies  against  unique  cell 
surface  antigens,  it  should  be possible using the  liposome 
technique to direct molecules, capable of specifically affecting 
a variety of physiologic responses, to subgroups of heteroge- 
nous cell  populations. Despite the above-mentioned limita- 
tions, such a procedure should be applicable to a wide range 
of neurobiological and endocrine systems in which it is desir- 
able to specifically modify particular intracellular events cou- 
pled to physiologic responses only detectable in intact multi- 
cellular populations. 
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